Vertex Fails to Convince UK Watchdog of CRISPR Therapy Casgevy’s Value

A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.